

In the Claims:

Please amend Claims 1-2, 19-21 and 28-30. Claims 3-6, 13-18 and 22-24 are withdrawn. Please add new Claims 31 and 32. Claims 1-2, 9-12, 19-21, 25, 26 and 29-31 are pending.

1. (Currently amended) A method for detecting gastric cancer, comprising:
 - (a) providing a sample of blood; and
 - (b) detecting over-expression of [[a]] cystatin SN ("CST1") protein having the sequence of SEQ ID NO:108, serum proteinase inhibitor, Clade H (heat shock protein 47) member 1 (collagen binding protein 1), ("SERPINH1") and inhibin beta A ("INHBA") in said blood sample.

2. (Currently amended) The method of claim 1, further comprising detecting over-expression of at least one additional GTM family member protein selected from the group consisting of matrix metalloproteinase 12 (MMP12), ~~inhibin ("INHBA")~~, insulin-like growth factor 7 ("IGFBP7"), gamma-glutamyl hydrolase ("GGH"), leucine proline-enriched proteoglycan ("LEPRE1"), cystatin S ("CST4"), secreted frizzled-related protein 4 ("SFRP4"), asporin ("ASPN"), cell growth regulator with EF hand domain 1 ("CGREF1"), kallikrein, tissue inhibitor of metalloproteinase 1 ("TIMP1"), secreted acidic cysteine-rich protein ("SPARC"), transforming growth factor ("TGFB1"), EGF-containing fibulin-like extracellular matrix protein 2 ("EFEMP2"), lumican ("LUM"), stannin ("SNN"), secreted phosphoprotein 1 ("SPP1"), chondroitin sulfate proteoglycan 2 ("CSPG2"), carboxypeptidase N ("CPN2"), N-acylsphingosine amidohydrolase ("ASAHI"), serine protease 11 ("PRSS11"), secreted frizzled-related protein 2 ("SFRP2"), phospholipase A2, group XIIB ("PLA2G12B"), spondin 2 ("SPON2"), extracellular matrix protein ("SPON2"), olfactomedin 1 ("OLFM1"), thrombospondin repeat containing 1 ("TSRC1"), thrombospondin 2 ("THBS2"), adlcan, cystatin SA ("CST2"), lysyl oxidase-like enzyme 2 ("LOXL2"), thyroglobulin ("TG"), transforming growth factor beta1 ("TGFB1"), transforming growth factor beta induced protein ("TGFB-I"), ~~serine or cysteine proteinase inhibitor clade H ("SERPINH1")~~, serine or cysteine proteinase inhibitor clade B ("SERPINB5"), matrix metalloproteinase 2 ("MMP2"), proprotein convertase subtilisin/kexin type 5 ("PCSK5"), kallikrein 10 ("KLK10"), hyaluronin and proteoglycan link protein 4 ("HAPLN4"), serine protease 11 ("PRSS11"), and transmembrane 6 superfamily member 2 ("TM6SF2").

3. (Withdrawn) The method of claim 2, wherein said step of detecting is carried out by detecting over-expression of GTM mRNA.

4. (Withdrawn) The method of claim 2, wherein said step of detecting is carried out by detecting over-expression of GMT cDNA.

5. (Withdrawn) The method of claim 4, wherein said step of detecting is carried out using an oligonucleotide complementary to at least a portion of said GMT cDNA.

6. (Withdrawn) The method of claim 4, wherein said step of detecting is carried out using qPCR method using a forward primer and a reverse primer.

7-8. Canceled

9. (Previously amended) The method of claim 1, said step of detecting being carried out using an antibody directed against said CST1 protein.

10. (Previously amended) The method of claim 9, said step of detecting being carried out using a sandwich-type immunoassay method.

11. (Previously amended) The method of claim 9, said antibody being a monoclonal antibody.

12. (Previously amended) The method of claim 9, said antibody being a polyclonal antiserum.

13. (Withdrawn) A device for detecting a GTM, comprising:
a substrate having a GTM capture reagent thereon; and
a detector associated with said substrate, said detector capable of detecting a GTM associated with said capture reagent.

14. (Withdrawn) The device of claim 13, wherein said GTM capture reagent is an oligonucleotide.

15. (Withdrawn) The device of claim 13, wherein said GTM capture reagent is an antibody.

16. (Withdrawn) A kit for detecting cancer, comprising:
a substrate having a GTM capture reagent thereon;

a means for visualizing a complex of said GMT capture agent and a GMT;
 reagents; and
 instructions for use.

17. (Withdrawn) The kit of claim 16, wherein said GTM capture reagent is a GTM-specific oligonucleotide.

18. (Withdrawn) The kit of claim 16, wherein said GTM capture reagent is a GTM-specific antibody selective for a GTM-oligonucleotide, a GTM protein or a GTM peptide.

19. (Currently amended) A method for detecting gastric cancer, comprising the steps of:
 providing a blood sample from a patient suspected of having gastric cancer;
 measuring the presence in said blood sample of [[a]] cystatin SN protein having the sequence of SEQ ID NO:108, serum proteinase inhibitor, Clade H (heat shock protein 47) member 1 (collagen binding protein 1), ("SERPINH1") and inhibin beta A ("INHBA"); and

comparing the amount of said cystatin SN protein, SERPINH1 and INHBA present in said blood sample with a threshold value that distinguishes a normal cystatin SN protein levels from a cancer-indicative level.

20. (Currently amended). A method for screening for gastric cancer, comprising the steps of:
 providing a blood sample from a test subject;
 measuring the presence in said blood sample of a cystatin SN protein having the sequence of SEQ ID NO:108, serum proteinase inhibitor, Clade H (heat shock protein 47) member 1 (collagen binding protein 1), ("SERPINH1") and inhibin beta A ("INHBA"); and

comparing the amount of said cystatin SN protein, SERPINH1 and INHBA present in said blood sample with [[a]] corresponding values of said cystatin SN, SERPINH1 and INHBA value obtained from a control sample from a subject not having gastric cancer, and

finding over-expression of said cystatin SN protein, SERPINH1 and INHBA present in said blood sample with [[a]] corresponding values of said cystatin SN, in said blood sample compared to said control sample when the presence of said cystatin SN protein present in said blood sample with values of said cystatin SN, SERPINH1 and INHBA meet meets or exceeds a threshold value over the control sample.

21. (Currently amended) The method of claim 19, further comprising detecting over-expression of at least one additional GTM family member protein selected from the group consisting of MMP12, ~~INHBA~~, IGFBP7, GGH, LEPRE1, CST4, SFRP4, ASPN, CGREF1, KLK10, TIMP1, SPARC, TGFB1, EFEMP2, LUM, SNN, SPPI, CSPG2, ASAH1, PRSS11, SFRP2, PLA2G12B, SPON2, OLFM1, TSRC1, THBS2, adlcan, CST2, LOXL2, TG, TGFB1, ~~SERPINH~~, SERPINB5, MMP2, PCSK5 and TM6SF2.

22. (Withdrawn) The method of claim 19, wherein said GTM is an oligonucleotide specific for a GTM.

23. (Withdrawn) The method of claim 22, wherein said oligonucleotide is DNA.

24. (Withdrawn) The method of claim 22, wherein said oligonucleotide is RNA.

25. (Previously amended) The method of claim 19, said step of measuring using an ELISA assay.

26. (Previously amended) The method of claim 19, said test sample being obtained from plasma.

27. (Canceled)

28. (Currently amended) The method of claim 1, further comprising measuring over-expression of ~~SERPINH~~ or SERPINB5 in said blood sample.

29. (Currently amended) The method of claim 1, further comprising measuring over-expression of one or more of SFRP4, SFRP2, TSRC1, THBS2, LOXL2, ~~SERPINH~~, SERPINB5, and CGR11 in said blood sample.

30. (Currently amended) The method of claim 1, further comprising measuring over-expression of one or more proteins selected from the group consisting of adlcan, ASPN, CSPG2, cystatin SA ("CST2"), cystatin S ("CST4"), EFEMP2, GGH, ~~INHBA~~, IGFBP7, LKL10, LEPRE1, LUM, LOXL2, MMP12, TIMP1, ASAH1, SPP1, SFRP2, SFRP4, CGR11, THBS2, SPARC, PRSS11, TG, and TGFB1 in said blood sample.

Please add the following new claims.

31. (New) A method for detecting gastric cancer, comprising:
- (a) providing a sample from said patient; and
 - (b) detecting over-expression of a cystatin SN ("CST1") protein having a molecular weight higher than that found in subjects not having gastric cancer.
32. (New) The method of Claim 31, where said molecular weight of said CST1 in said patient is about 35 kD, about 45 kD, or about 65 kD.